Quotient Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Quotient stock.
View analyst ratings for Quotient or view top-rated stocks.

Wall Street analysts have given Quotient a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Quotient wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Quotient is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Quotient.

Quotient will be holding an earnings conference call on Thursday, August 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "4861155".

Quotient Limited (NASDAQ:QTNT) posted its earnings results on Monday, May, 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.13. The company earned $9.64 million during the quarter, compared to the consensus estimate of $8.90 million. Quotient had a negative trailing twelve-month return on equity of 6,699.81% and a negative net margin of 250.05%.
View Quotient's earnings history.

Quotient's stock was trading at $4.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, QTNT stock has decreased by 26.7% and is now trading at $3.40.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued 1-year target prices for Quotient's stock. Their forecasts range from $5.00 to $13.50. On average, they anticipate Quotient's stock price to reach $9.25 in the next year. This suggests a possible upside of 172.1% from the stock's current price.
View analysts' price targets for Quotient or view top-rated stocks among Wall Street analysts.

Some companies that are related to Quotient include Meridian Bioscience (VIVO), Alpha Teknova (TKNO), Aspira Women's Health (AWH), OncoCyte (OCX), Lucira Health (LHDX), MyMD Pharmaceuticals (MYMD), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), ImmuCell (ICCC), Navidea Biopharmaceuticals (NAVB), Trinity Biotech (TRIB), Biomerica (BMRA), Achieve Life Sciences (ACHV), ARCA biopharma (ABIO) and Global WholeHealth Partners (GWHP).
View all of QTNT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Verastem (VSTM), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX), Novavax (NVAX), Ocular Therapeutix (OCUL) and Sorrento Therapeutics (SRNE).

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Quotient's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.05%). Company insiders that own Quotient stock include Edward Farrell, Jeremy Stackawitz, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd.
View institutional ownership trends for Quotient.

QTNT stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have bought Quotient stock in the last two years include Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von.
View insider buying and selling activity for Quotient or or view top insider-buying stocks.

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QTNT stock can currently be purchased for approximately $3.40.

Quotient has a market capitalization of $345.19 million and generates $43.38 million in revenue each year. The company earns $-108,470,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

Quotient employs 435 workers across the globe.

The official website for Quotient is www.quotientbd.com.

Quotient is headquartered at B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800 or via email at [email protected]